Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

<p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious...

Celý popis

Podrobná bibliografie
Hlavní autoři: Kavanaugh, A, Coates, LC, Mease, PJ, Nowak, M, Hippeli, L, Lehman, T, Banerjee, S, Merola, JF
Médium: Journal article
Jazyk:English
Vydáno: Oxford University Press 2024